脳卒中エキスパート　抗血栓療法を究める

出版社： 中外医学社
著者：
発行日： 2019-01-30
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498328228
電子書籍版： 2019-01-30 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,620 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,620 円(税込)

購入する

商品紹介

脳卒中診療における特に重要なテーマについて、各領域の専門家がテーマ毎に1冊で理解できるように詳説するシリーズ第一弾。抗血栓療法に焦点を合わせ、コモンな病型から特殊な病態、高リスクな脳梗塞まで抗血栓療法の奥義をエキスパートが伝授する。力強い内容で、幅広くかつ深く掘り下げられた解説は、病態についての理解を深め、治療や予防にあたって最良の選択をする手助けとなる。

目次

  • I．脳梗塞の病態に応じて抗血栓療法を究める
    　1　アテローム血栓症の病態と抗血栓療法
    　　1．抗血栓療法からみたアテローム血栓症の病態
    　　2．アテローム血栓症の障害血管と抗血栓療法の選択
    　　3．アテローム血栓症急性期の抗血栓療法
    　　4．アテローム血栓症慢性期の抗血栓療法
    　2　心原性脳塞栓症の病態と抗血栓療法
    　　1．心原性脳塞栓症の原因疾患
    　　2．心房細動の病態と抗血栓薬の選択
    　　3．心房細動を伴わない弁膜症と人工弁
    　　4．その他の心疾患
    　3　小血管病：古典的ラクナ梗塞と分枝粥腫病（branch atheromatous disease）
    　　1．ラクナ梗塞とは
    　　2．ラクナ梗塞の臨床症状
    　　3．ラクナ梗塞の定義と臨床診断
    　　4．ラクナ梗塞の危険因子
    　　5．ラクナ梗塞の発症機序
    　　6．分枝粥腫病（BAD）とは
    　　7．分枝粥腫病の定義と診断
    　　8．分枝粥腫病の疫学
    　　9．分枝粥腫病の臨床症状の特徴
    　　10．分枝粥腫病の危険因子
    　　11．分枝粥腫病の病態と画像診断
    　　12．ラクナ梗塞および分枝粥腫病の急性期治療
    　　13．ラクナ梗塞および分枝粥腫病の慢性期再発治療と転帰
    　4　脳動脈解離と抗血栓療法
    　　1．脳動脈解離とは
    　　2．脳動脈解離の症状
    　　3．脳動脈解離の診断
    　　4．脳動脈解離の治療
    　　5．脳動脈解離に対する抗血栓療法
    　5　無症候性脳梗塞，無症候性頸部・頭蓋内脳動脈狭窄・閉塞
    　　1．無症候性脳梗塞の診断および臨床的意義
    　　2．無症候性脳梗塞に対する治療方針
    　　3．無症候性頸動脈狭窄・閉塞の臨床的意義とその診断
    　　4．無症候性頸動脈狭窄・閉塞に対する治療方針
    　　5．無症候性頭蓋内動脈狭窄・閉塞の臨床的意義とその診断
    　　6．無症候性頭蓋内動脈狭窄・閉塞に対する治療方針

    II．抗血小板療法・抗凝固療法を究める
    　1　抗血小板薬の特徴と使い分け
    　　1．抗血小板薬の作用機序
    　　2．脳梗塞治療における抗血小板療法
    　2　DAPTの有効性と安全性　
    　　1．アスピリンの効果と限界
    　　2．急性期の強化抗血栓療法
    　　3．抗血小板薬併用療法
    　　4．抗血小板薬併用療法と単剤療法の比較：メタ解析
    　　5．急性期DAPTの積極的適応
    　3　ワルファリンおよびDOACの特徴と使い分け　
    　　1．経口抗凝固薬の適応
    　　2．各種経口抗凝固薬の特徴
    　　3．ワルファリンとDOACの使い分け
    　　4．抗凝固療法の基本
    　4　抗凝固療法と抗血小板療法の併用
    　　1．血栓止血学的にみた，抗凝固療法と抗血小板療法の併用
    　　2．併用する場合の両治療法の投与設定は？

    III．　特殊な状況・疾患における抗血栓療法を究める
    　1　抗血栓療法中の出血性事象への対処法
    　　1．抗血栓療法中脳内出血の治療と抗血栓薬再開のめど
    　　2．観血的処置のための抗血栓薬の一時中断や中和，またその再開について
    　　3．脳梗塞超急性期アルテプラーゼ・機械的血栓除去術のための抗凝固薬の中和について
    　2　脳微小出血，アミロイド血管症を合併した症例での抗血栓療法
    　　1．脳微小出血とは？
    　　2．脳微小出血と脳血管障害発症リスク
    　　3．血栓溶解療法との関連
    　　4．脳微小出血と抗血栓療法
    　3　透析患者における抗血栓療法
    　　1．透析症例の一般予後
    　　2．透析患者における抗血栓療法
    　4　Trousseau症候群に対する抗血栓療法
    　　1．概念の変遷
    　　2．Trousseau症候群の定義
    　　3．検査所見
    　　4．担がん患者における脳梗塞発症機序
    　　5．脳梗塞を発症しやすい悪性腫瘍
    　　6．担がん患者における凝固能亢進機序
    　　7．凝固能亢進（DIC）に対する治療
    　　8．脳梗塞再発予防のための治療
    　　9．VTE再発予防のための治療
    　5　抗リン脂質抗体症候群，高ホモシステイン血症，先天性血栓性素因への抗血栓療法
    　　1．抗リン脂質抗体症候群
    　　2．高ホモシステイン血症
    　　3．先天性血栓性素因
    　6　脳静脈・静脈洞閉塞症への抗血栓療法
    　　1．脳静脈洞血栓症の病態
    　　2．脳静脈洞血栓症の症候
    　　3．脳静脈洞血栓症の臨床検査
    　　4．脳静脈洞血栓症の画像診断
    　　5．脳静脈洞血栓症の抗血栓療法
    　　6．脳静脈洞血栓症の血管内治療，開頭血腫除去術
    　7　CADASIL，CARASIL，もやもや病への抗血栓療法
    　　1．CADASIL，CARASILへの抗血栓療法
    　　2．もやもや病への抗血栓療法
    　8　ESUS，奇異性脳塞栓症への抗血栓療法
    　　1．ESUS
    　　2．奇異性脳塞栓症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 脳梗塞の病態に応じて抗血栓療法を究める

P.15 掲載の参考文献
1) Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke. 1981 ; 12 : 723-5.
PubMed
2) Saver JL, Goyal M, van der Lugt A, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke : a meta-analysis. JAMA. 2016 ; 316 : 1279-88.
PubMed
3) Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke : a meta-analysis of individual patient data from randomised trials. Lancet. 2014 ; 384 : 1929-35.
PubMed
4) Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mismatch analysis in acute stroke. JMRI. 2010 ; 32 : 1024-37.
PubMed
5) Group CCASTC. Cast : Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (chinese acute stroke trial) collaborative group. Lancet. 1997 ; 349 : 1641-9.
 
6) Group ISTC. The international stroke trial (ist) : a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International stroke trial collaborative group. Lancet. 1997 ; 349 : 1569-81.
 
7) Wang Y, Zhao X, Liu L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 ; 369 : 11-9.
PubMed
8) Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection : the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial. Circulation. 2005 ; 111 : 2233-40.
PubMed
9) Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study) : a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010 ; 9 : 489-97.
PubMed
10) Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER) : a randomised controlled pilot trial. Lancet Neurol. 2007 ; 6 : 961-9.
PubMed
11) Lee YS, Bae HJ, Kang DW, et al. Cilostazol in acute ischemic stroke treatment (CAIST trial) : a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011 ; 32 : 65-71.
 
12) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 ; 324 : 71-86.
PubMed
13) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Caprie steering committee. Lancet. 1996 ; 348 : 1329-39.
 
14) Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2) : An aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 ; 9 : 959-68.
PubMed
15) Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke : a randomised, double-blind, pilot study. Lancet Neurol. 2008 ; 7 : 494-9.
 
16) Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The warfarin-aspirin symptomatic intracranial disease (WASID) study group. Stroke. 1998 ; 29 : 1389-92.
 
P.31 掲載の参考文献
1) Stoddard MF, Dawkins PR, Prince CR, et al. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event : a transesophageal echocardiographic study. J Am Coll Cardiol. 1995 ; 25 : 452-9.
 
2) Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surgery. 1996 ; 61 : 755-9.
PubMed
3) Topcuoglu MA, Liu L, Kim D-E, et al. Updates on prevention of cardioembolic strokes. J Stroke. 2018 ; 20 : 180-96.
PubMed
4) Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation : Results from the ROCKET-AF trial. Eur Heart J. 2015 ; 36 : 288-96.
PubMed
5) Fauchier L, Philippart R, Clementy N, et al. How to define valvular atrial fibrillation? Arch Cardiovasc Dis. 2015 ; 108 : 530-9.
PubMed
6) Albers GW. Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med. 1994 ; 154 : 1443-8.
PubMed
7) Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation : Japan atrial fibrillation stroke trial. Stroke. 2006 ; 37 : 447-51.
PubMed
8) Hart RG, Pearce LA, Aguilar MI. Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 ; 146 : 857-67.
PubMed
9) Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011 ; 364 : 806-17.
PubMed
10) Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation. 1994 ; 89 : 635-41.
PubMed
P.45 掲載の参考文献
1) Pantoni L. Cerebral small vessel disease : from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010 ; 9 : 689-701.
PubMed
2) Fisher CM. Lacunes : small, deep cerebral infarcts. Neurology. 1965 ; 15 : 774-84.
PubMed
3) Fisher CM. Ataxic hemiparesis. A pathologic study. Arch Neurol. 1978 ; 35 : 126-8.
PubMed
4) Special report from the national institute of neurological disorders and stroke. Classification of cerebrovascular diseases iii. Stroke. 1990 ; 21 : 637-76.
PubMed
5) Fisher CM. Lacunar strokes and infarcts : a review. Neurology. 1982 ; 32 : 871-6.
PubMed
6) Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Toast. Trial of org 10172 in acute stroke treatment. Stroke. 1993 ; 24 : 35-41.
 
7) Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke. 2005 ; 36 : 891-901.
PubMed
8) Futrell N. Lacunar infarction : embolism is the key. Stroke. 2004 ; 35 : 1778-9.
PubMed
9) Wardlaw JM, Sandercock PA, Dennis MS, et al. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia- Stroke. 2003 ; 34 : 806-12.
PubMed
10) Marinkovic SV, Milisavljevic MM, Kovacevic MS, et al. Perforating branches of the middle cerebral artery. Microanatomy and clinical significance of their intracerebral segments. Stroke. 1985 ; 16 : 1022-9.
PubMed
11) Caplan LR. Intracranial branch atheromatous disease : a neglected, understudied, and underused concept. Neurology. 1989 ; 39 : 1246-50.
PubMed
12) 星野晴彦, 高木誠, 山本康正, 他. Branch atheromatous diseaseにおける進行性脳梗塞の頻度と急性期転帰. 脳卒中. 2011 ; 2011 : 37-44.
Medical*Online
13) Bladin PF, Berkovic SF. Striatocapsular infarction : Large infarcts in the lenticulostriate arterial territory. Neurology. 1984 ; 34 : 1423-30.
PubMed
14) Nakase T, Yamamoto Y, Takagi M, Japan Branch Atheromatous Disease Registry C. The impact of diagnosing branch atheromatous disease for predicting prognosis. J Stroke Cerebrovasc Dis. 2015 ; 24 : 2423-8.
 
15) Yamamoto Y, Nagakane Y, Makino M, et al. Aggressive antiplatelet treatment for acute branch atheromatous disease type infarcts : a 12-year prospective study. Int J Stroke. 2014 ; 9 : E8.
PubMed
16) Nishi R, Mano T, Kobayashi Y, et al. Argatroban, aspirin, and clopidogrel combination therapy for acute penetrating artery infarction : a pilot study. Brain Nerve. 2016 ; 68 : 181-9.
PubMed
17) Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study : a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000 ; 9 : 147-57.
PubMed
18) Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (csps 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 ; 9 : 959-68.
PubMed
19) Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match) : randomised, double-blind, placebo-controlled trial. Lancet. 2004 ; 364 : 331-7.
PubMed
20) Benavente OR, Hart RG, McClure LA, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012 ; 367 : 817-25.
 
21) Wilson LK, Pearce LA, Arauz A, et al. Morphological classification of penetrating artery pontine infarcts and association with risk factors and prognosis : the SPS3 trial. Int J Stroke. 2016 ; 11 : 412-9.
PubMed
22) Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001 ; 345 : 1444-51.
PubMed
23) Suto Y, Nakayasu H, Maeda M, et al. Long-term prognosis of patients with large subcortical infarctions. Eur Neurol. 2009 ; 62 : 304-10.
PubMed
24) 日本脳卒中学会 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015 [追補 2017 対応] . 東京 : 協和企画 ; 2017. p.65, 103.
 
P.61 掲載の参考文献
1) 山脇健盛. 脳動脈解離. In : 高嶋修太郎, 伊藤義彰, 編. 必携脳卒中ハンドブック. 第3版. 東京 : 診断と治療社 ; 2017. p.367-75.
 
2) 頭蓋内・外脳動脈解離. In : 日本脳卒中学会 脳卒中合同ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015 [追補 2017 対応] . 東京 : 協和企画 ; 2017. p.244-7.
 
3) Morel A, Naggara O, Touze E, et al. Mechanism of ischemic infarct in spontaneous cervical artery dissection. Stroke. 2012 ; 43 : 1354-61.
PubMed
4) Menon R, Kerry S, Norris JW, et al. Treatment of cervical artery dissection : a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2008 ; 79 : 1122-7.
PubMed
5) Sarikaya H, da Costa BR, Baumgartner RW, et al. Antiplatelets versus anticoagulants for the treatment of cervical artery dissection : Bayesian meta-analysis. PLoS ONE. 2013 ; 8 : e72697.
PubMed
6) Lyrer P, Engelter ST. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev. 2003 : CD000255.
 
7) Lyrer P, Engelter ST. Antithrombotic drugs for carotid artery dissection. Cochrane Database Syst Rev. 2010 : CD000255.
 
8) CADISS trial investigators, Markus HS, Hayter E, et al. Anti- platelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS) : a randomised trial. Lancet Neurol. 2015 ; 14 : 361-7.
 
9) Molina CA, Alvarez-Sabin J, Schonewille W, et al. Cerebral microembolism in acute spontaneous internal carotid artery dissection. Neurology. 2000 ; 55 : 1738-40.
PubMed
10) Machet A, Fonseca AC, Oppenheim C, et al. Does anticoagulation promote mural hematoma growth or delayed occlusion in spontaneous cervical artery dissections? Cerebrovasc Dis. 2013 ; 35 : 175-81.
PubMed
11) Gensicke H, Ahlhelm F, Jung S, et al. New ischaemic brain lesions in cervical artery dissection stratified to antiplatelets or anticoagulants. Eur J Neurol. 2015 ; 22 : 859-65.
PubMed
12) Engelter ST, Traenka C, Lyrer P. Dissection of cervical and cerebral arteries. Curr Neurol Neurosci Rep. 2017 ; 17 : 59.
PubMed
13) Mustanoja S, Metso TM, Putaala J, et al. Helsinki experience on nonvitamin K oral anticoagulants for treating cervical arterydissection. Brain Behav. 2015 ; 5 : e00349.
 
14) Caprio FZ, Bernstein RA, Alberts MJ, et al. Efficacy and safety of novel oral anticoagulants in patients with cervical artery dissections. Cerebrovasc Dis. 2014 ; 38 : 247-53.
PubMed
15) 高木誠. 治療の現状と指針 内科的治療 文献reviewと手引き. In : 国立循環器病センター内科脳血管部門, 編. 脳動脈解離診療の手引き. 大阪 : 国立循環器病センター内科脳血管部門 ; 2009. p.32-5.
 
16) Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 ; 45 : 2160-236.
PubMed
17) Kim BM, Kim SH, Kim DI, et al. Outcomes and prognostic factors of intracranial unruptured vertebrobasilar artery dissection. Neurology. 2011 ; 76 : 1735-41.
PubMed
18) Engelter ST, Rutgers MP, Hatz F, et al. Intravenous thrombolysis in stroke attributable to cervical artery dissection. Stroke. 2009 ; 40 : 3772-6.
PubMed
19) Engelter ST, Dallongeville J, Kloss M, et al. Thrombolysis in cervical artery dissection-data from the Cervical Artery Dissection and Ischaemic Stroke Patients (CADISP) database. Eur J Neurol. 2012 ; 19 : 1199-206.
 
20) Lin J, Sun Y, Zhao S, et al. Safety and efficacy of thrombolysis in cervical artery dissection-related ischemic stroke : a meta-analysis of observational studies. Cerebrovasc Dis. 2016 ; 42 : 272-9.
PubMed
P.76 掲載の参考文献
1) 細矢貴亮, 佐々木真理. 研修医必携救急で役立つ頭部CT・MRI. 東京 : 南江堂 ; 2006.
 
2) 小林祥泰, 卜蔵浩和, 高橋一夫, 他. 脳ドックにおける頭蓋内狭窄病変の自然歴. 脳卒中. 2004 ; 26 : 624-8.
Medical*Online
3) Vermeer SE, Hollander M, van Dijk EJ, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population : the Rotterdam Scan Study. Stroke. 2003 ; 34 : 1126-9.
PubMed
4) Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005 ; 45 : 1243-8.
PubMed
5) Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373 : 1849-60.
PubMed
6) 日本脳卒中学会 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015 [追補 2017 対応] . 東京 : 協和企画 ; 2017. p.216-8.
 
7) Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993 ; 24 : 35-41.
 
8) Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention : the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001 ; 285 : 2370-5.
PubMed
9) Mannami T, Konishi M, Baba S, et al. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city : the Suita study. Stroke. 1997 ; 28 : 518-25.
PubMed
10) Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA. 1995 ; 273 : 1421-8.
PubMed
11) Nighoghossian N, Derex L, Douek P, et al. The vulnerable carotid artery plaque. Current imaging method and new perspectives. Stroke. 2005 ; 36 : 2764-72.
PubMed
12) Saito K, Nagatsuka K, Ishibashi-Ueda H, et al. Contrast-enhanced ultrasound for the evaluation of neovascularization in atherosclerotic carotid artery plaques. Stroke. 2014 ; 45 : 3073-5.
PubMed
13) Watanabe Y, Nagayama M. MR imaging of carotid atherosclerotic plaque. J Jpn Coll Angiol. 2011 ; 51 : 89-94.
 
14) Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis : systematic review and up-to-date meta-analysis. Stroke. 2004 ; 35 : 2902-9.
PubMed
15) Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation : results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol. 2013 ; 62 : 909-17.
 
16) Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients : the GLAGOV randomized clinical trial. JAMA. 2016 ; 316 : 2373-84.
 
17) 日本脳卒中学会 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015 [追補 2017 対応] . 東京 : 協和企画 ; 2017. p.223.
 
18) Yadav JS, Wholey MH, Kuntz RE, et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004 ; 351 : 1493-501.
PubMed
19) Rosenfield K, Matsumura JS, Chaturvedi S, et al ; ACT I Investigators. Randomized trial of stent versus surgery for asymptomatic carotid stenosis. N Engl J Med. 2016 ; 374 : 1011-20.
PubMed
20) 日本脳神経超音波学会・栓子検出と治療学会合同ガイドライン作成委員会. 頭蓋内超音波検査ガイドライン. Neurosonology. 2006 ; 19 : 113-31.
Medical*Online
21) Turan TN, Makki AA, Tsappidi S, et al. Risk factors associated with severity and location of intracranial arterial stenosis. Stroke. 2010 ; 41 : 1636-40.
PubMed
22) Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS) : the final results of a randomised trial. Lancet. 2013 ; 6736 : 1-9.
 
23) Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA. 1995 ; 273 : 1421-8.
PubMed
24) Halliday A, Mansfield A, Marro J, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms : randomised controlled trial. Lancet. 2004 ; 363 : 1491-502.
PubMed
25) Kasner SE, Chimowitz MI, Lynn MJ, et al. Warfarin Aspirin Symptomatic Intracranial Disease Trial Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation. 2006 ; 113 : 555-63.
PubMed
26) Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis : the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005 ; 36 : 782-6.
PubMed

II. 抗血小板療法・抗凝固療法を究める

P.95 掲載の参考文献
1) Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002 ; 105 : 1650-5.
PubMed
2) Johnston SC, Amarenco P, Albers GW, et al. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med. 2016 ; 375 : 35-43.
 
3) Uchiyama S, Ikeda Y, Urano Y, et al. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study : a randomized, double-blind, controlled trial. Cerebrovasc Dis. 2011 ; 31 : 601-13.
PubMed
4) Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate-aspirin comparative clinical study for efficacy and safety in secondary prevention of cerebral infarction (S-ACCESS) : a randomized, double-blind, aspirin-controlled trial. Stroke. 2008 ; 39 : 1827-33.
PubMed
5) Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients : subanalysis of the jelis trial. Stroke. 2008 ; 39 : 2052-8.
PubMed
6) Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 ; 44 : 691-8.
PubMed
7) Ciccone A, Motto C, Abraha I, et al. Glycoprotein iib-iiia inhibitors for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 : CD005208.
PubMed
8) Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : a combined analysis of 40000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the cast and ist collaborative groups. Stroke. 2000 ; 31 : 1240-9.
 
9) Lee YS, Bae HJ, Kang DW, et al. Cilostazol in acute ischemic stroke treatment (CAIST trial) : a randomized double-blind non-inferiority trial. Cerebrovasc Dis. 2011 ; 32 : 65-71.
 
10) Wang Y, Zhao X, Liu L, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 ; 369 : 11-9.
PubMed
11) Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. N Engl J Med. 2018 ; 379 : 215-25.
 
12) Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009 ; 373 : 1849-60.
PubMed
13) Sudlow CL, Mason G, Maurice JB, et al. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev. 2009 : CD001246.
PubMed
14) Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2) : an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010. 9 : 959-68.
PubMed
15) Kamal AK, Naqvi I, Husain MR, et al. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev. 2011 : CD008076.
 
16) Lee M, Saver JL, Hong KS, et al. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke : a systematic review and meta-analysis. Ann Intern Med. 2013 ; 159 : 463-70.
PubMed
17) Toyoda K, Uchiyama S, Hoshino H, et al. Protocol for cilostazol stroke prevention study for antiplatelet combination (CSPS. com) : a randomized, open-label, parallel-group trial. Int J Stroke. 2015 ; 10 : 253-8.
 
18) 日本脳卒中学会 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015 [追補 2017 対応] . 東京 : 協和企画 ; 2017. p.65, 83, 103.
 
P.107 掲載の参考文献
1) Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke. A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 ; 49 : e46-e110.
PubMed
2) The International Stroke Trial (IST). A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997 ; 349 : 1569-81.
 
3) CAST : randomized placebo-controlled trial of early aspirin early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997 ; 349 : 1641-9.
 
4) Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : a combined analysis of 40000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke. 2000 ; 31 : 1240-8.
 
5) Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 ; 369 : 11-9.
PubMed
6) Wang Y, Pan Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack (CHANCE) trial. One-year outcomes. Circulation. 2015 ; 132 : 40-6.
 
7) Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER) : a randomised controlled pilot trial. Lancet Neurol. 2007 ; 6 : 961-9.
PubMed
8) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2015〔追補 2017 対応〕. 東京 : 協和企画 ; 2017. p.103-14.
 
9) Wong KS, Chen C, Fu J, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolization in patients with acute symptom cerebral or carotid artery stenosis (CLAIR study) : a randomized, open-label, blinded-endpoint trial. Lancet Neurol. 2010 ; 9 : 489-97.
PubMed
10) Li Z, Wang Y, Zhao X, et al. Treatment effect of clopidogrel plus aspirin within 12 hours of acute minor stroke or transient ischemic attack. J Am Heart Assoc. 2016 ; 5 : e003038.
PubMed
11) Johnston C, Easton JD, Farrant M, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018 ; 379 : 215-25.
 
12) Dengler R, Diener HC, Schwartz A, et al. Early treatment with aspirin plus extended-release dipyridamole for transient ischemic attack or ischemic stroke within 24 h of symptom onset (EARLY trial) : a randomised, open-label, blinded-endpoint trial. Lancet Neurol. 2010 ; 9 : 159-66.
PubMed
13) Bath PM, Woodhouse LJ, Appleton JP, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dypiridamole in patients with acute cerebra, ischaemia (TARDIS) : a randomized, open-label, phase 3 superiority trial. Lancet. 2018 ; 391 : 850-9.
 
14) http://www2.nms.ac.jp/ads/ (2018年4月7日アクセス)
 
15) Wong KS, Wang Y, Leng X, et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack. An updated systematic review and meta-analysis. Circulation. 2013 ; 128 : 1656-6.
 
16) 山上宏. 急性期抗血栓療法. In : 豊田一則, 編. 脳梗塞診療読本. 第2版. 東京 : 中外医学社 ; 2016. p.117-37.
 
17) Liu Y, Fei Z, Wang W, et al. Efficacy and safety of short-term dual-versus mono-antiplatelet therapy in patients with ischemic stroke or TIA : a meta-analysis of 10 randomizsed controlled trials. J Neurol. 2016 ; 263 : 2247-59.
 
18) Jing J, Meng X, Zhao X, et al. Dual antiplatelet therapy in transient ischemic attack and minor stroke with different infarction patterns. Subgroup analysis of CHANCE randomized clinical trial. JAMA Neurol. published online March 26, 2018. doi : 10.1001/jamaneurol.2018.0247
 
P.121 掲載の参考文献
1) 高嶋修太郎, 伊藤義彰, 編. 必携脳卒中ハンドブック. 第3版. 東京 : 診断と治療社 ; 2017.
 
2) 日本脳卒中学会 脳卒中ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015 [追補 2017 対応] . 東京 : 協和企画 ; 2017.
 
3) 日本循環器学会. 心房細動治療 (薬物) ガイドライン (2013年改訂版). [http://www.j-circ.or.jp/guideline/pdf/JCS2013_inoue_h.pdf]
 
4) Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 ; 361 : 1139-51.
PubMed
5) Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365 : 883-91.
PubMed
6) Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 ; 365 : 981-92.
PubMed
7) Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 ; 369 : 2093-104.
PubMed
8) Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation. A systematic review and meta-analysis. Stroke. 2017 ; 48 : 2494-503.
PubMed
9) Comerota AJ, Ramacciotti E. A comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism. Am J Med Sci. 2016 ; 352 : 92-106.
PubMed
10) Lim HY, Nandurkar H, Ho P. Direct oral anticoagulants and the paradigm shift in the management of venous thromboembolism. Semin Thromb Hemost. 2018 ; 44 : 261-6.
PubMed
11) Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 ; 352 : 305-16.
 
12) Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996 ; 335 : 540-6.
PubMed
13) Yasaka M, Minematsu K, Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med. 2001 ; 40 : 1183-8.
PubMed
14) Tepper PG, Liu X, Hamilton M, et al. Ischemic stroke in nonvalvular atrial fibrillation at warfarin initiation. Assessment via a large insurance database. Stroke. 2017 ; 48 : 1487-94.
 
15) Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation : a meta-analysis of randomised trials. Lancet. 2014 ; 383 : 955-62.
PubMed
16) Wang KL, Lip GY, Lin SJ, et al. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation : meta-analysis. Stroke. 2015 ; 46 : 2555-61.
PubMed
17) Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation : systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017 ; 359 : j5058.
PubMed
18) Shinoda N, Mori M, Tamura S, et al. Risk of recurrent ischemic stroke with unintended low-dose oral anticoagulant therapy and optimal timing of review. J Stroke Cerebrovasc Dis. 2018 ; 27 : 1546-51.
PubMed
19) Rottenstreich A, Zacks N, Kleinstern G, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. J Thromb Thrombolysis. 2018 ; 45 : 543-9.
PubMed
20) Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 ; 37 : 2893-962.
PubMed
21) 田口芳治, 高嶋修太郎, 道具伸浩, 他. 非弁膜症性心房細動に起因した心原性脳塞栓症発症時の抗血栓療法の状況に関する検討. 脳卒中. 2011 ; 33 : 551-8.
Medical*Online
22) Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial. Lancet. 2013 ; 381 : 1107-15.
PubMed
23) Yamashita Y, Hamatani Y, Esato M, et al. Clinical characteristics and outcomes in extreme elderly (age-85 years) Japanese patients with atrial fibrillation : the Fushimi AF registry. Chest. 2016 ; 149 : 401-12.
PubMed
24) Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation : a nationwide cohort study. Circulation. 2018 ; 138 : 37-47.
PubMed
P.131 掲載の参考文献
1) Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001 ; 345 (20) : 1444-51.
PubMed
2) Design, progress and challenges of a double-blind trial of warfarin versus aspirin for symptomatic intracranial arterial stenosis. Neuroepidemiology. 2003 ; 22 : 106-17.
PubMed
3) Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 ; 352 : 1305-16.
PubMed
4) Saito S, Isshiki T, Kimura T, et al. Efficacy and safety of adjusted- dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome : the PRASFIT-ACS study. Circ J. 2014 ; 78 : 1684-92.
PubMed
5) Isshiki T, Kimura T, Ogawa H, et al. Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. Circulation. 2014 ; 78 : 2926-34.
 
6) 上田雅之, 濱本真, 長尾毅彦, 他. 高齢者脳血栓症急性期に対するオザグレル, ヘパリン併用療法の検討. 脳卒中. 1996 ; 18 : 118-23.
 
7) Dewilde W, Berg JT. Design and rationale of the WOEST trial : What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST). Am Heart J. 2009 ; 158 : 713-8.
PubMed
8) Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention : an open-label, randomised, controlled trial. Lancet. 2013 ; 381 : 1107-15.
PubMed
9) Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J. 2015 ; 169 : 472-8.
 
10) Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016 ; 375 : 2423-34.
PubMed
11) Cannon CP, Gropper S, Bhatt DL, et al. Design and rationale of the RE-DUAL PCI trial : a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016 ; 39 : 555-64.
 
12) Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017 ; 377 : 1513-24.
PubMed

III. 特殊な状況・疾患における抗血栓療法を究める

P.145 掲載の参考文献
Demchuk AM, Dowlatshahi D, Rodriguez-Luna D, et al. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT) : a prospective observational study. Lancet Neurol. 2012 : 11 ; 307-14.
PubMed
Sporns PB, Schwake M, Schmidt R, et al. Computed tomographic blend sign is associated with computed tomographic angiography spot sign and predicts secondary neurological deterioration after intracerebral hemorrhage. Stroke. 2017 ; 48 : 131-5.
PubMed
Li Q, Zhang G, Xiong X, et al. Black hole sign. Novel imaging marker that predicts hematoma growth in patients with intracerebral hemorrhage. Stroke. 2016 ; 47 : 1777-81.
 
Boulous G Morotti A, Charidimou A, et al. Association between hypodensities detected by computed tomography and hematoma expansion in patients with intracranial hemorrhage. JAMA Neurol. 2016 ; 73 : 961-8.
 
Li Q, Liu Q-J, Yang W-S, et al. An imaging predictor for early hematoma expansion and poor outcome in patients with intracerebral hemorrhage. Stroke. 2017 ; 48 : 3019-25.
PubMed
P.146 掲載の参考文献
1) Anderson CS, Heeley E, Huang Y, et al ; INTERACT2 Investigators. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013 ; 368 : 2355-65.
PubMed
2) Koga M, Toyoda K, Yamagami H, et al ; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage : a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). J Hypertens. 2012 ; 30 : 2357-64.
PubMed
3) Sakamoto Y, Koga M, Yamagami H, et al ; SAMURAI Study Investigators. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage : the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke. 2013 ; 44 : 1846-51.
 
4) Tsivgoulis G, Katsanos AH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage : a meta-analysis. Neurology. 2014 ; 83 : 1523-9.
PubMed
5) Qureshi, AI, Palesch YY, Barsan WG, et al ; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016 ; 375 : 1033-43.
PubMed
6) Butcher KS, Jeerakathil T, Hill M, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke. 2013 ; 44 : 620-6.
PubMed
7) Mayer SA, Brun NC, Begtrup K, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008 ; 358 : 2127-37.
PubMed
8) Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH) : a randomised trial. Lancet Neurol. 2016 ; 15 : 566-73.
 
9) Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015 ; 373 : 511-20.
PubMed
10) Kuramatsu JB, Gerner ST , Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015 ; 313 : 824-36.
PubMed
10) Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH) : a randomised, open-label, phase 3 trial. Lancet. 2016 ; 387 : 2605-13.
 
11) Pennlert J, Overholser R, Asplund K, et al. Optimal timing of anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation. Stroke. 2017 ; 48 : 314-20.
PubMed
12) Yoshida K, Takahashi JC, Takenobu Y, et al. Stroke associated with pregnancy and puerperium. A nationwide study by the Japan Stroke Society. Stroke. 2017 ; 48 : 276-82.
PubMed
13) Jorgensen ME, Torp-Pedersen C, Gislason GH, et al. Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. JAMA. 2014 ; 312 : 269-77.
PubMed
14) Douketis JD, Spyropoulos AC, Kaatz S, et al ; BRIDGE Investigators. Perioperative bridging amicoagulation in patients with atrial fibrillation. N Engl J Med. 2015 ; 373 : 823-33.
PubMed
P.159 掲載の参考文献
1) Offenbacher H, Fazekas F, Schmidt R, et al. MR of cerebral abnormalities concomitant with primary intracerebral hematomas. AJNR Am J Neuroradiol. 1996 ; 17 : 573-8.
PubMed
2) Fazekas F, Kleinert R, Roob G, et al. Histopathologic analysis of foci of signal loss on gradient-echo T2* -weighted MR images in patients with spontaneous intracerebral hemorrhage : evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999 ; 20 : 637-42.
PubMed
3) Wang Z, Soo YO, Mok VC. Cerebral microbleeds : is antithrombotic therapy safe to administer- Stroke. 2014 ; 45 : 2811-7.
PubMed
4) Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds : systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007 ; 130 : 1988-2003.
PubMed
5) Kwa VI, Franke CL, Verbeeten B Jr, et al. Silent intracerebral microhemorrhages in patients with ischemic stroke : Amsterdam Vascular Medicine Group. Ann Neurol. 1998 ; 44 : 372-7.
PubMed
6) Kato H, Izumiyama M, Izumiyama K, et al. Silent cerebral microbleeds on T2* -weighted MRI : correlation with stroke subtype, stroke recurrence, and leukoaraiosis. Stroke. 2002 ; 33 : 1536-640.
PubMed
7) Poels MM, Vernooij MW, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds : an update of the Rotterdam scan study. Stroke. 2010 ; 41 : S103-6.
PubMed
8) Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham heart study. Stroke. 2014 ; 45 : 1492-4.
PubMed
9) Akoudad S, Portegies ML, Koudstaal PJ, et al. Cerebral microbleeds are associated with an increased risk of stroke : The Rotterdam Study. Circulation. 2015 ; 132 : 509-16.
PubMed
10) Bokura H, Saika R, Yamaguchi T, et al. Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals. Stroke. 2011 ; 42 : 1867-71.
PubMed
11) Wilson D, Charidimou A, Ambler G, et al. Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA : a meta-analysis. Neurology. 2016 ; 87 : 1501-10.
 
12) Charidimou A, Kakar P, Fox Z, et al. Cerebral microbleeds and recurrent stroke risk : systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke. 2013 ; 44 : 995-1001.
PubMed
13) Lim JS, Hong KS, Kim GM, et al. Cerebral microbleeds and early recurrent stroke after transient ischemic attack : results from the Korean Transient Ischemic Attack Expression Registry. JAMA Neurol. 2015 ; 72 : 301-8.
PubMed
14) Charidimou A, Karayiannis C, Song TJ, et al. Brain microbleeds, anticoagulation, and hemorrhage risk : meta-analysis in stroke patients with AF. Neurology. 2017 ; 89 : 2317-26.
PubMed
15) Charidimou A, Imaizumi T, Moulin S, et al. Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds : a meta-analysis. Neurology. 2017 ; 89 : 820-9.
 
16) Charidimou A, Shoamanesh A ; International META-MICROBLEEDS Initiative. Clinical relevance of microbleeds in acute stroke thrombolysis : comprehensive meta-analysis. Neurology. 2016 ; 87 : 1534-41.
PubMed
17) Charidimou A, Turc G, Oppenheim C, et al. Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis : individual patient data meta-analysis. Stroke. 2017 ; 48 : 2084-90.
PubMed
18) Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden. A meta-analysis. JAMA Neurol. 2016 ; 73 : 675-83.
 
19) Lovelock CE, Cordonnier C, Naka H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage : a systematic review of published and unpublished studies. Stroke. 2010 ; 41 : 1222-8.
PubMed
20) Akoudad S, Darweesh SK, Leening MJ, et al. Use of coumarin anticoagulants and cerebral microbleeds in the general population. Stroke. 2014 ; 45 : 3436-9.
PubMed
21) Wang Z, Xu C, Wang P, et al. Combined clopidogrel-aspirin treatment for high risk TIA or minor stroke does not increase cerebral microbleeds. Neurol Res. 2015 ; 11 : 993-7.
 
22) van Etten ES, Auriel E, Haley KE, et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke. 2014 ; 45 : 2280-5.
PubMed
23) Pasquini M, Benedictus MR, Boulouis G, et al. Incident cerebral microbleeds in a cohort of intracerebral hemorrhage. Stroke. 2016 ; 47 : 689-94.
 
24) O'Donnell MJ, Eikelboom JW, Yusuf S, et al. Effect of apixaban on brain infarction and microbleeds : AVERROES-MRI assessment study. Am Heart J. 2016 ; 178 : 145-50.
PubMed
25) Saito T, Kawamura Y, Sato N, et al. Non-vitamin K antagonist oral anticoagulants do not increase cerebral microbleeds. J Stroke Cerebrovasc Dis. 2015 ; 24 : 1373-7.
 
26) Soo YO, Yang SR, Lam WW, et al. Risk vs benefit of anti-thrombotic therapy in ischaemic stroke patients with cerebral microbleeds. J Neurol. 2008 ; 255 : 1679-86.
PubMed
27) Soo YO, Siu DY, Abrigo J, et al. Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. Stroke. 2012 ; 43 : 1532-6.
PubMed
28) Fisher M. MRI screening for chronic anticoagulation in atrial fibrillation. Front Neurol. 2013 ; 4 : 137.
PubMed
29) Selim M, Diener HC. Atrial fibrillation and microbleeds. Stroke. 2017 ; 48 : 2660-4.
PubMed
30) Shoamanesh A, Charidimou A, Sharma M, et al. Should patients with ischemic stroke or transient ischemic attack with atrial fibrillation and microbleeds be anticoagulated? Stroke. 2017 ; 48 : 3408-12.
 
P.167 掲載の参考文献
1) Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease. Lancet Neurol. 2014 ; 13 : 823-33.
PubMed
2) Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke : a systematic review and meta-analysis. Nephrol Dial Transplant. 2015 ; 30 : 1162-9.
PubMed
3) Tanaka K, Watanabe T, Takeuchi A, et al. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017 ; 91 : 227-34.
PubMed
4) Iguchi Y, Kimura K, Kobayashi K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol. 2008 ; 102 : 1056-9.
PubMed
5) Watanabe H, Watanabe T, Sasaki S, et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation : the Niigata preventive medicine study. Am Heart J. 2009 ; 158 : 629-36.
PubMed
6) Beyer-Westendorf J, Kreutz R, Posch F, et al. The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. Int J Cardiol. 2018 ; 253 : 71-7.
 
7) Sandsmark DK, Messe SR, Zhang X, et al. Proteinuria, but not eGFR, predicts stroke risk in chronic kidney disease : chronic renal insufficiency cohort study. Stroke. 2015 ; 46 : 2075-80.
 
8) Konno S, Munakata M. Moderately increased albuminuria is an independent risk factor of cardiovascular events in the general Japanese population under 75 years of age : the Watari study. PloS One. 2015 ; 10 : e0123893.
PubMed
9) Tanaka F, Komi R, Makita S, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens. 2016 ; 34 : 506-12.
PubMed
10) Ishigami J, Grams ME, Naik RP, et al. Hemoglobin, albuminuria, and kidney function in cardiovascular risk : the ARIC (atherosclerosis risk in communities) study. J Am Heart Assoc. 2018 ; 7 : e007209.
PubMed
11) Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes : a collaborative meta-analysis of individual participant data. Lancet Diabet Endocrinol. 2015 ; 3 : 514-25.
 
12) Vinhas J, Barreto C, Assuncao J, et al. Treatment of anaemia with erythropoiesis-stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk : a meta-analysis. Nephron Clini Pract. 2012 ; 121 : c95-101.
PubMed
13) Georgakis MK, Chatzopoulou D, Tsivgoulis G, et al. Albuminuria and cerebral small vessel disease : a systematic review and meta-analysis. J Am Geriatr Soc. 2018 ; 66 : 509-17.
PubMed
14) Watanabe A. Cerebral microbleeds and intracerebral hemorrhages in patients on maintenance hemodialysis. J Stroke Cerebrovasc Dis. 2007 ; 16 : 30-3.
PubMed
15) Shima H, Ishimura E, Naganuma T, et al. Cerebral microbleeds in predialysis patients with chronic kidney disease. Nephrol Dial Transplant. 2010 ; 25 : 1554-9.
PubMed
16) Naganuma T, Takemoto Y, Shoji T, et al. Cerebral microbleeds predict intracerebral hemorrhage in hemodialysis patients. Stroke. 2015 ; 46 : 2107-12.
PubMed
17) Sakamoto N, Ishikawa E, Aoki K, et al. Clinical outcomes of intracerebral hemorrhage in hemodialysis patients. World Neurosurg. 2014 ; 81 : 538-42.
PubMed
18) Molshatzki N, Orion D, Tsabari R, et al. Chronic kidney disease in patients with acute intracerebral hemorrhage : association with large hematoma volume and poor outcome. Cerebrovasc Diseases. 2011 ; 31 : 271-7.
PubMed
19) Shimoyama T, Kimura K, Shibazaki K, et al. Maintenance hemodialysis independently increases the risk of early death after acute intracerebral hemorrhage. Cerebrovasc Dis. 2013 ; 36 : 47-54.
PubMed
20) Wetmore JB, Ellerbeck EF, Mahnken JD, et al. Atrial fibrillation and risk of stroke in dialysis patients. Ann Epidemiol. 2013 ; 23 : 112-8.
PubMed
21) Kawamura M, Fijimoto S, Hisanaga S, et al. Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis. 1998 ; 31 : 991-6.
PubMed
22) Iseki K, Fukiyama K. Clinical demographics and long-term prognosis after stroke in patients on chronic haemodialysis. the Okinawa dialysis study (OKIDS) group. Nephrol Dial Transplant. 2000 ; 15 : 1808-13.
PubMed
23) Sozio SM, Armstrong PA, Coresh J, et al. Cerebrovascular disease incidence, characteristics, and outcomes in patients initiating dialysis : the choices for healthy outcomes in caring for ESRD (CHOICE) study. Am J Kidney Dis. 2009 ; 54 : 468-77.
PubMed
24) Power A, Chan K, Singh SK, et al. Appraising stroke risk in maintenance hemodialysis patients : a large single-center cohort study. Am J Kidney Dis. 2012 ; 59 : 249-57.
PubMed
25) Toyoda K, Fujii K, Fujimi S, et al. Stroke in patients on maintenance hemodialysis : a 22-year single-center study. Am J Kidney Dis. 2005 ; 45 : 1058-66.
PubMed
26) Kodani E, Atarashi H, Inoue H, et al. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation : a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes. 2018 ; 4 : 59-68.
 
27) Hiremath S, Holden RM, Fergusson D, et al. Antiplatelet medications in hemodialysis patients : a systematic review of bleeding rates. Clin J Am Soc Nephrol. 2009 ; 4 : 1347-55.
PubMed
28) Alexopoulos D, Panagiotou A. Oral antiplatelet agents and chronic kidney disease. Hellenic J Cardiol. 2011 ; 52 : 509-15.
PubMed
29) Aksu HU, Oner E, Celik O, et al. Aspirin resistance in patients undergoing hemodialysis and effect of hemodialysis on aspirin resistance. Clin Appl Thromb Hemost. 2015 ; 21 : 82-6.
PubMed
30) Baber U, Chandrasekhar J, Sartori S, et al. Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention : a report from the PROMETHEUS study. JACC Cardiovasc Interv. 2017 ; 10 : 2017-25.
PubMed
31) Jeong KH, Cho JH, Woo JS, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis : a randomized crossover study. Am J Kidney Dis. 2015 ; 65 : 916-24.
PubMed
32) Kim JS, Woo JS, Kim JB, et al. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. Int J Cardiol. 2017 ; 238 : 110-6.
PubMed
33) Wang H, Qi J, Li Y, et al. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease. Br J Clin Pharmacol. 2018 ; 84 : 88-96.
 
34) Jain N, Reilly RF. Oral P2Y12 receptor inhibitors in hemodialysis patients undergoing percutaneous coronary interventions : current knowledge and future directions. Semin Dial. 2016 ; 29 : 374-81.
PubMed
35) Woo JS, Kim W, Lee SR, et al. Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel : results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney disease (PIANO-2 CKD) randomized study. Am Heart J. 2011 ; 162 : 1018-25.
 
36) Zhou Y, Pan Y, Wu Y, et al. Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack : CHANCE substudy (clopidogrel in high-risk patients with acute nondisabling cerebrovascular events). Stroke. 2016 ; 47 : 2791-6.
 
37) Ikeme JC, Pergola PE, Scherzer R, et al. Post hoc analyses of randomized clinical trial for the effect of clopidogrel added to aspirin on kidney function. Clin J Am Soc Nephrol. 2017 ; 12 : 1040-7.
PubMed
38) Chen CY, Lee KT, Lee CT, et al. Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. Int J Stroke. 2014 ; 9 : 580-90.
PubMed
39) Kessler M, Moureau F, Nguyen P. Anticoagulation in chronic hemodialysis : progress toward an optimal approach. Semin Dial. 2015 ; 28 : 474-89.
PubMed
40) Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012 ; 367 : 625-35.
PubMed
41) Wakasugi M, Kazama JJ, Tokumoto A, et al. Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation : a prospective cohort study. Clin Exp Nephrol. 2014 ; 18 : 662-9.
PubMed
42) Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure : the Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015 ; 36 : 297-306.
PubMed
43) Li J, Wang L, Hu J, et al. Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation : a systematic review and a meta-analysis. Nutr Metab Cardiovasc Dis. 2015 ; 25 : 706-13.
 
44) Wong CX, Odutayo A, Emdin CA, et al. Meta-analysis of anticoagulation use, stroke, thromboembolism, bleeding, and mortality in patients with atrial fibrillation on dialysis. Am J Cardiol. 2016 ; 117 : 1934-41.
PubMed
45) Tan J, Liu S, Segal JB, et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation : a systematic review and meta-analysis. BMC Nephrol. 2016 ; 17 : 157.
PubMed
46) Van Der Meersch H, De Bacquer D, De Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation : a systematic review and meta-analysis. Am Heart J. 2017 ; 184 : 37-46.
PubMed
47) Harel Z, Chertow GM, Shah PS, et al. Warfarin and the risk of stroke and bleeding in patients with atrial fibrillation receiving dialysis : a systematic review and meta-analysis. Can J Cardiol. 2017 ; 33 : 737-46.
PubMed
48) Tsai C, Marcus LQ, Patel P, et al. Warfarin use in hemodialysis patients with atrial fibrillation : a systematic review of stroke and bleeding outcomes. Can J Kidney Health Dis. 2017 ; 4 : 2054358117735532.
PubMed
49) Kumar S, de Lusignan S, McGovern A, et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation : a population based study from UK primary care. BMJ. 2018 ; 360 : k342.
PubMed
50) Potpara TS, Ferro CJ, Lip GYH. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol. 2018 ; 14 : 337-51.
PubMed
51) Kai B, Bogorad Y, Nguyen LN, et al. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm. 2017 ; 14 : 645-51.
PubMed
52) Chen JJ, Lin LY, Yang YH, et al. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation--a nation-wide database analyses. Int J Cardiol. 2014 ; 177 : 1008-11.
 
53) Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016 ; 67 : 2888-99.
PubMed
54) Di Lullo L, Ronco C, Cozzolino M, et al. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Research. 2017 ; 155 : 38-47.
PubMed
55) Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease : patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017 ; 10 : 135-43.
PubMed
56) Feldberg J, Patel P, Farrell A, et al. A systematic review of direct oral with atrial fibrillation. Nephrol Dial Transplant. 2018 Mar 2. Epub 2018/03/07.
 
57) Shroff GR, Stoecker R, Hart A. Non-vitamin K-dependent oral anticoagulants for nonvalvular atrial fibrillation in patients with CKD : pragmatic considerations for the clinician. Am J Kidney Dis. 2018 May 2. Epub 2018/05/08.
 
58) Ando G, Capranzano P. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with chronic kidney disease : a systematic review and network meta-analysis. Int J Cardiology. 2017 ; 231 : 162-9.
 
P.187 掲載の参考文献
1) Kuramoto K, Matsushita S, Yamanouchi H. Nonbacterial thrombotic endocarditis as a cause of cerebral and myocardial infarction. Jap Circ J. 1984 ; 48 (9) : 1000-6.
PubMed
2) Callander N, Rapaport SI. Trousseau's syndrome. West J Med. 1993 ; 158 (4) : 364-71.
 
3) 野川茂. がんと脳梗塞-トルーソー症候群の臨床. 日本血栓止血学会誌. 2016 ; 27 : 18-28.
 
4) Lopez JA, Ross RS, Fishbein MC, et al. Nonbacterial thrombotic endocarditis : a review. Am Heart J. 1987 ; 113 (3) : 773-84.
PubMed
5) Biller J, Challa VR, Toole JF, et al. Nonbacterial thrombotic endocarditis. A neurologic perspective of clinicopathologic correlations of 99 patients. Arch Neurol. 1982 ; 39 (2) : 95-8.
PubMed
6) Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine. 1985 ; 64 (1) : 16-35.
PubMed
7) Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer : incidence and etiology. Neurology. 2004 ; 62 (11) : 2025-30.
PubMed
8) Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability-Stroke. 1994 ; 25 (6) : 1215-8.
PubMed
9) Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms : clinical, pathophysiologic, and therapeutic features. Medicine. 1977 ; 56 (1) : 1-37.
PubMed
10) Planner RS, O'Sullivan EF, Campbell JJ, et al. The hypercoagulable state and pulmonary embolism in patients with ovarian carcinoma. Aust N Z J Obstet Gynaecol. 1978 ; 18 (3) : 209-12.
PubMed
11) Evans TR, Mansi JL, Bevan DH. Trousseau's syndrome in association with ovarian carcinoma. Cancer. 1996 ; 77 (12) : 2544-9.
PubMed
12) Varki A. Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood. 2007 ; 110 (6) : 1723-9.
PubMed
13) Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer. 1997 ; 80 (4) : 649-55.
PubMed
14) Gonmori H, Maekawa T, Kobayashi N, et al. The role of tissue thromboplastin in the development of DIC accompanying neoplastic diseases. Bibliotheca haematologica. 1983 ; (49) : 23-39.
PubMed
15) Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant : a cysteine proteinase from malignant tissue. Biochemistry. 1985 ; 24 (20) : 5558-67.
PubMed
16) Nanninga PB, van Teunenbroek A, Veenhof CH, et al. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost. 1990 ; 64 (3) : 361-4.
PubMed
17) Pineo GF, Regoeczi E, Hatton MW, et al. The activation of coagulation by extracts of mucus : a possible pathway of intravascular coagulation accompanying adenocarcinomas. J Lab Clin Med. 1973 ; 82 (2) : 255-66.
PubMed
18) Donati MB. Cancer and thrombosis : from Phlegmasia alba dolens to transgenic mice. Thromb Haemost. 1995 ; 74 (1) : 278-81.
PubMed
19) Ornstein DL, Zacharski LR, Memoli VA, et al. Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues. Cancer. 1991 ; 68 (5) : 1061-7.
PubMed
20) Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987 ; 18 (3) : 275-84.
PubMed
21) Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease : CHEST Guideline and Expert Panel Report. Chest. 2016 ; 149 (2) : 315-52.
 
22) Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer : the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004 ; 22 (10) : 1944-8.
PubMed
23) Nakano K, Sugiyama K, Satoh H, et al. Effect of thrombomodulin alfa on disseminated intravascular coagulation in patients with lung cancer. Intern Med. 2017 ; 56 (14) : 1799-806.
PubMed
24) Yoshii Y, Numata T, Ishitobi W, et al. Lung adenocarcinoma complicated by Trousseau's syndrome successfully treated by a combination of anticoagulant therapy and chemotherapy. Intern Med. 2014 ; 53 (16) : 1835-9.
PubMed
25) Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018 ; 378 (23) : 2191-201.
PubMed
26) Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005 ; 92 (10) : 1212-20.
PubMed
27) Buller HR, Decousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 ; 369 (15) : 1406-15.
PubMed
28) Raskob GE, van Es N, Segers A, et al. Edoxaban for venous thromboembolism in patients with cancer : results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 ; 3 (8) : e379-87.
PubMed
29) Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 ; 378 (7) : 615-24.
PubMed
30) Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism : results of a randomized trial (SELECT-D). J Clin Oncol. 2018 ; 36 (20) : 2017-23.
 
P.197 掲載の参考文献
1) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4 : 295-306.
 
2) Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The antiphospholipid antibodies in stroke study (APASS) group. Neurology. 1993 ; 43 : 2069-73.
PubMed
3) Hess DC, Krauss J, Adams RJ, et al. Anticardiolipin antibodies : a study of frequency in tia and stroke. Neurology. 1991 ; 41 : 525-8.
PubMed
4) 北川泰久, 大熊壮尚, 徳岡健太郎. 【若年者の脳卒中】抗リン脂質抗体陽性脳梗塞. BRAIN and NERVE. 2008 ; 60 : 1144-58.
 
5) Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999 ; 30 : 1561-5.
PubMed
6) Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. The antiphospholipid antibodies in stroke study group. Stroke. 1990 ; 21 : 1268-73.
 
7) Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke. 1997 ; 28 : 1660-5.
 
8) Muir KW, Squire IB, Alwan W, et al. Anticardiolipin antibodies in an unselected stroke population. Lancet. 1994 ; 344 : 452-6.
 
9) Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992 ; 117 : 997-1002.
PubMed
10) Rosove MH, Brewer PM. Antiphospholipid thrombosis : clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992 ; 117 : 303-8.
PubMed
11) Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 ; 332 : 993-7.
PubMed
12) Okuma H, Kitagawa Y, Yasuda T, et al. Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome. Int J Med Sci. 2009 ; 7 : 15-8.
PubMed
13) Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004 ; 291 : 576-84.
PubMed
14) Lubbe WF, Butler WS, Palmer SJ, et al. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1983 ; 1 : 1361-3.
PubMed
15) 日本脳卒中学会 脳卒中合同ガイドライン委員会, 編. 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
16) McCully KS. Homocysteine and vascular disease. Nat Med. 1996 ; 2 : 386-9.
PubMed
17) Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 1993 ; 92 : 1400-6.
PubMed
18) Harker LA, Slichter SJ, Scott CR, et al. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med. 1974 ; 291 : 537-43.
PubMed
19) Perry IJ, Refsum H, Morris RW, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995 ; 346 : 1395-8.
PubMed
20) Alfthan G, Pekkanen J, Jauhiainen M, et al. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective finnish population based study. Atherosclerosis. 1994 ; 106 : 9-19.
 
21) Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke prevention : a meta-analysis. Lancet. 2007 ; 369 : 1876-82.
 
22) Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality : meta-analysis of 8 randomized trials involving 37485 individuals. Arch Intern Med. 2010 ; 170 : 1622-31.
 
23) Morris JG, Singh S, Fisher M. Testing for inherited thrombophilias in arterial stroke : can it cause more harm than good? Stroke. 2010 ; 41 : 2985-90.
PubMed
24) Sakata T, Kario K, Katayama Y, et al. Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res. 1999 ; 94 : 69-78.
PubMed
25) 永山富子, 津田道雄, 清ゆかり, 他. 先天性プラスミノーゲン異常症の分子遺伝学的解析と臨床的意義に関する研究. 脳卒中. 1992 ; 14 : 395-401.
 
P.211 掲載の参考文献
1) Saposnik G, Barinagarrementeria F, Brown RD Jr, et al. Diagnosis and management of cerebral venous thromobosis. A statement for healthcare professional from the American Heart Asociation/American Stroke Association. Stroke. 2011 ; 42 : 1158-92.
 
2) Canhao P, Ferro JM, Lindgren AG, et al. Causes and predictors off death in cerebral venous thromobosis. Stroke 2005 ; 36 : 1720-5.
 
3) Dentali F, Squizzato A, Marchesi C, et al. D-dimer testing in the diagnosis of cerebral vein thromobosis : a systematic review and a meta-analysis of the literature. J Thrombosis Haemostatis. 2012 ; 10 : 582-9.
 
4) Ferro JM, Canhao P, Stam J, et al. Prognosis of cerebral vein and dural sinus thrombosis : results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004 ; 35 : 664-70.
 
5) Ferro JM, Bacelar-Nicolau H, Rodrigues T, et al. Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis. Cerebrovasc Dis. 2009 ; 28 (1) : 39-44.
PubMed
6) Duman T, Uluduz D, Midi I, et al. A multicenter study of 1144 patients with cerebral venous thrombosis : the VENOST study. J Stroke Cerebrovasc Dis. 2017 ; 26 : 1848-57.
PubMed
7) Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991 ; 338 : 597-600.
PubMed
8) de Bruijn SF, Stam J. et al. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999 ; 30 : 484-8.
PubMed
9) Coutinho JM, Ferro JM, Canhao P, et al. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke. 2010 ; 41 : 2575-80.
PubMed
10) Misra UK, Kalita J, Chandra S, et al. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis : a randomized controlled trial. Eur J Neurol. 2012 ; 19 : 1030-6.
 
11) Ferro JM, Bousser MG, Canhao P, et al. European stroke organization guideline for the diagnosis and treatment of cerebral venousthrombosis-endorsed by the European Academy of Neurology. Eur J Neurol. 2017 ; 24 : 1203-13.
 
12) Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 ; 45 : 2160-236.
PubMed
13) Aguiar de Sousa D, Canhao P, Crassard I, et al. Safety of Pregnancy After Cerebral Venous Thrombosis : Results of the ISCVT (International Study on Cerebral Vein and Dural Sinus Thrombosis) -2 PREGNANCY Study. Stroke. 2017 ; 48 : 3130-3.
 
14) Mendonca MD, Barbosa R, Cruz-e-Silva V, et al. Oral direct thrombin inhibitor as an alternative in the management of cerebral venous thrombosis : a series of 15 patients. Int J Stroke. 2015 ; 10 : 1115-8.
PubMed
15) Geisbusch C, Richter D, Herweh C, et al. Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis : first experience in 7 patients. Stroke. 2014 ; 45 : 2469-71.
PubMed
16) Siddiqui FM, Dandapat S, Banerjee C, et al. Mechanical thrombectomy in cerebral venous thrombosis : systematic review of 185 cases. Stroke. 2015 ; 46 : 1263-8.
PubMed
17) Ilyas A, Chen CJ, Raper DM, et al. Endovascular mechanical thrombectomy for cerebral venous sinus thrombosis : a systematic review. J Neurointerv Surg. 2017 ; 9 : 1086-92.
PubMed
18) Coutinho JM, Ferro JM, Zuurbier SM, et al. Thrombolysis or antico-agulation for cerebral venous thrombosis : rationale and design of the TO-ACT trial. Int J Stroke. 2013 ; 8 : 135-40.
 
19) Ferro JM, Crassard I, Coutinho JM, et al. Decompressive surgery in cerebral venous thromobosis. A multicenter registry and a systematic review of individual patients data. Stroke. 2011 ; 42 : 2825-31.
 
P.224 掲載の参考文献
1) Herve D, Chabriat H. Cadasil. J Geriatr Psychiatry Neurol. 2010 ; 23 : 269-76.
PubMed
2) Bersano A, Bedini G, Oskam J, et al. CADASIL : Treatment and management options. Curr Treat Options Neurol. 2017 ; 19 : 31.
 
3) 水野敏樹. 【あしたの脳梗塞】CADASIL の診断と治療. BRAIN and NERVE. 2013 ; 65 : 811-23.
 
4) 内野誠. 皮質下性血管障害の病態と治療CADASIL の病態と治療. 臨床神経学. 2011 ; 51 : 945-8.
 
5) Fukutake T, Hirayama K. Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol. 1995 ; 35 : 69-79.
 
6) 野崎洋明. 小血管病の謎に迫るCARASIL病態研究の最前線CARASILの病態機序への考察. 臨床神経学. 2012 ; 52 : 1360-2.
 
7) Nozaki H, Nishizawa M, Onodera O. Features of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke. 2014 ; 45 : 3447-53.
PubMed
8) Dichgans M, Holtmannspotter M, Herzog J, et al. Cerebral microbleeds in CADASIL : a gradient-echo magnetic resonance imaging and autopsy study. Stroke. 2002 ; 33 : 67-71.
PubMed
9) Ragoschke-Schumm A, Axer H, Fitzek C, et al. Intracerebral haemorrhage in CADASIL. J Neurol Neurosurg Psychiatry. 2005 ; 76 : 1606-7.
PubMed
10) Oh JH, Lee JS, Kang SY, et al. Aspirin-associated intracerebral hemorrhage in a patient with CADASIL. Clin Neurol Neurosurg. 2008 ; 110 : 384-6.
 
11) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
12) 清水久央, 長見周平, 高橋信行. ロメリジン投与にて脳梗塞抑制効果が示唆されたcerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) の1例. 臨床神経学. 2014 ; 54 : 22-6.
 
13) Kuroda S, Houkin K. Moyamoya disease : current concepts and future perspectives. Lancet Neurol. 2008 ; 7 : 1056-66.
PubMed
14) Funaki T, Takahashi JC, Yoshida K, et al. Periventricular anastomosis in moyamoya disease : detecting fragile collateral vessels with MR angiography. J Neurosurg. 2016 ; 124 : 1766-72.
PubMed
15) Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011 ; 56 : 34-40.
 
16) Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011 ; 6 : e22542.
PubMed
17) Miyawaki S, Imai H, Takayanagi S, et al. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis/occlusion. Stroke. 2012 ; 43 : 3371-4.
PubMed
18) Miyamoto S, Yoshimoto T, Hashimoto N, et al. Effects of extracranial-intracranial bypass for patients with hemorrhagic moyamoya disease : results of the Japan Adult Moyamoya Trial. Stroke. 2014 ; 45 : 1415-21.
PubMed
19) Kraemer M, Berlit P, Diesner F, et al. What is the expert's option on antiplatelet therapy in moyamoya disease- Results of a worldwide survey. Eur J Neurol. 2012 ; 19 : 163-7.
 
20) Research Committee on the P, Treatment of Spontaneous Occlusion of the Circle of W, Health Labour Sciences Research Grant for Research on Measures for Infractable D. Guidelines for diagnosis and treatment of moyamoya disease (spontaneous occlusion of the circle of Willis). Neurol Med Chir (Tokyo). 2012 ; 52 : 245-66.
 
21) Zhao Y, Zhang Q, Zhang D, et al. Effect of aspirin in postoperative management of adult ischemic moyamoya disease. World Neurosurg. 2017 ; 105 : 728-31.
 
22) Kuroda S, Group AS. Asymptomatic moyamoya disease : literature review and ongoing AMORE study. Neurol Med Chir (Tokyo). 2015 ; 55 : 194-8.
 
23) Kuroda S, Hashimoto N, Yoshimoto T, et al. Radiological findings, clinical course, and outcome in asymptomatic moyamoya disease : results of multicenter survey in Japan. Stroke. 2007 ; 38 : 1430-5.
PubMed
P.237 掲載の参考文献
1) Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source : the case for a new clinical construct. Lancet Neurol. 2014 ; 13 : 429-38.
PubMed
2) 北川一夫. 【脳卒中治療の最前線】Embolic Stroke of Undetermined Sources (ESUS) の病態. 神経治療学. 2016 ; 33 : 382-6.
 
3) 高橋愼一, 大木宏一, 鈴木則宏. 癌と脳卒中. 脳卒中. 2015 ; 37 : 395-402.
Medical*Online
4) Diener HC, Easton JD, Granger CB, et al. Design of randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke. 2015 ; 10 : 1309-12.
PubMed
5) Kasner SE, Lavados P, Sharma M, et al. Characterization of patients with embolic strokes of undetermined source in the NAVIGATE ESUS randomized trial. J Stroke Cerebrovasc Dis. 2018 ; 27 : 1673-82.
 
6) Amarenco P, Davis S, Jones EF, et al. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke. 2014 ; 45 : 1248-57.
PubMed
7) Varki A. Trousseau's syndrome : multiple definitions and multiple mechanisms. Blood. 2007 ; 110 : 1723-9.
PubMed
8) Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation 2005 ; 112 : 1063-72.
PubMed
9) Dalen JE, Alpert JS. Cryptogenic strokes and patent foramen ovales : What's the right treatment- Am J Med. 2016 ; 129 : 1159-62.
PubMed
10) Bedeir K, Volpi J, Ramlawi B. Cryptogenic stroke with a patent foramen ovale : medical therapy, percutaneous intervention, or surgery. J Card Surg. 2016 ; 31 : 156-60.
 
11) Homma S, Sacco RL, Di Tullio MR, et al. Effect of medical treatment in stroke patients with patent foramen ovale : patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002 ; 105 : 2625-31.
PubMed
12) Kent DM, Dahabreh IJ, Ruthazer R, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale : an individual participant data meta-analysis. Eur Heart J. 2015 ; 36 : 2381-9.
PubMed
13) 日本脳卒中学会 脳卒中ガイドライン委員会. 脳卒中治療ガイドライン 2015. 東京 : 協和企画 ; 2015.
 
14) Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013 ; 81 : 619-25.
PubMed
15) Ozdogru I, Kaya MG, Dogan A, et al. Thrombus crossing through a patent foramen ovale. Int J Cardiol. 2009 ; 133 : e55-56.
PubMed
16) Serra W, De Iaco G, Reverberi C, et al. Pulmonary embolism and patent foramen ovale thrombosis : the key role of TEE. Cardiovasc Ultrasound. 2007 ; 5 : 26.
PubMed
17) Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017 ; 377 : 1022-32.
PubMed
18) Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017 ; 377 : 1011-21.
 
19) Sondergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017 ; 377 : 1033-42.
 

書評

最近チェックした商品履歴

Loading...